05

2024-12

Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses

Baoyuan Zhang, Zhixiang Zhang, Jiaming Gao, Shiqiang Lu, Ran Pang, Dongfang Li, Xun Huang, Natasha Qin, Leo Liu, Zaiqi Wang 1. iScience, Volume 0, Issue 0, 111536

01

2024-06

Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study

Gao J, Cheng J, Xie W, Zhang P, Liu X, Wang Z, Zhang B. 2024 Jun;33(6):639-651.

30

2024-01

Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

Qiao M, Zhou F, Liu X, Jiang T, Wang H, Li X, Zhao C, Cheng L, Chen X, Ren S, Wang Z, Zhou C. Exp Hematol Oncol. 2024 Jan 30;13(1):11.

25

2024-01

Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling

Tan X, Kong D, Tao Z, Cheng F, Zhang B, Wang Z, Mei Q, Chen C, Wu K. Biomark Res. 2024 Jan 25;12(1):13

15

2023-05

Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling

Gao J, Yao Y, Liu C, Xie X, Li D, Liu P, Wang Z, Zhang B, Ren R. Int J Biol Sci. 2023 May 15;19(9):2711-2724.

07

2022-06

A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.

Lingying Wu, Jing Wang, Li Wang, Weiguo Lu, Ke Wang, An Lin, Ning Li, Li Li, Ning Su, Shuang Xie, Jun Jiang. ASCO Annual Meeting - April 8-13, 2022

< 12 > 前往